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Transcatheter Valve Technology
A Game Changer!*
John W. Moore, MD, MPH
San Diego, California
Rarely in one’s professional lifetime does one experience the
introduction of a game-changing technology. The trans-
catheter heart valve is a game changer. Only a few years ago,
transcatheter valve replacement was thought to be impossi-
ble. Today, however, this new technology heralds a revolu-
tion in valve replacement therapies that promises to extend
the lives of the “inoperable” and to offer less-invasive
alternatives to other patients.
See page 117
Available evidence already supports the use of transcatheter
valve technology in patients with severe senile calcific aortic
stenosis and in patients with pulmonary conduit valve dysfunc-
tion. With respect to aortic stenosis, the PARTNER (Place-
ment of AoRTic TraNscathetER Valve) trial results are
available for the cohort of patients deemed not suitable for
surgery (cohort B). In this cohort, patients having trans-
catheter aortic valve implantation with the Edwards Sapien
heart-valve system (Edwards Lifesciences, Irvine, Califor-
nia) experienced improved 1-year survival and reduced
repeat hospitalizations as compared with patients receiving
medical therapy (including balloon valvuloplasty) (1).
mong patients with congenital heart disease, it has not
een feasible to conduct adequately powered randomized
ontrolled studies such as the PARTNER trial. However,
atients with pulmonary conduit valve dysfunction have
een evaluated with a rigorous, single-arm, multicenter
ontrolled study, using performance criteria derived from
istorical data. Patients having implantation of the Melody
ranscutaneous pulmonary valve (Medtronic, Minneapolis,
innesota) were found to have 1-year safety and efficacy
utcomes similar to those expected from surgical valve/
onduit replacement (2). Although both the Sapien and the
elody devices are early generation technologies, the cur-
ent valve designs have been granted regulatory approvals in
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valve for aortic stenosis seems likely, given the PARTNER
trial results, and the Melody valve has already been granted
approval for pulmonary conduit valve dysfunction.
In this issue of the Journal, Roberts et al. (3) report an
“off-label” application for the Melody transcutaneous pul-
monary valve: replacement of the tricuspid valve. In their
report, Roberts et al. (3) have combined anecdotal experi-
ences from 8 active “Melody centers,” each of which
obtained institutional review board approval of Melody
valves for use in the tricuspid valve position. Fifteen patients
who had dysfunctional, surgically placed tricuspid biopros-
theses and subsequent percutaneous implantation of a Mel-
ody valve were identified and combined into a small case
series. Using percutaneous approaches, the authors success-
fully implanted Melody valves in stenotic and/or regurgitant
tricuspid tissue valves either in the orthotopic position or in
right atrium to right ventricle conduits. Patients undergoing
these procedures were uniformly symptomatic and high risk.
Among those treated primarily for valve stenosis, there was
an impressive drop in the mean valve gradient to only 3.9
mm Hg. Furthermore, no patient had more than mild
regurgitation after implantation, and most patients had no
detectable regurgitation. One critically ill patient died 20
days later from complications unrelated to valve implanta-
tion. Another patient required pacemaker implantation for
heart block, and a third patient developed endocarditis in
the Melody valve requiring device explant. At last follow-up
(median 4 months), 13 patients retained the Melody valve
in the tricuspid position, and 12 patients have experienced
improvement in New York Heart Association functional
class.
This is a limited report. It demonstrates that implanta-
tion of Melody valves to replace dysfunctional tissue valves
in the tricuspid position is feasible, usually functional, and
probably relatively safe. However, no definitive statements
about the durability of this valve in the tricuspid position,
about efficacy, or about safety can be made; nor does this
report add testimony to the controversy about whether
bioprosthetic or mechanical valves should be used to replace
dysfunctional tricuspid valves.
This report is significant because it chronicles a measured
step toward a new application for transcatheter valve tech-
nology. In doing so, it also opens the door for another
measured step in the same direction: use of the larger
diameter Sapien valve in similar clinical circumstances. As
compared with the Melody valve, the Sapien valve has the
potential advantage of extending the range of applicable
valve annuli or conduit diameters, and thereby expanding
the number of patients with tricuspid valve disease who may
be eligible for percutaneous valve therapy.
Through many such measured steps, transcatheter valve
technology will likely evolve and progress. For example,
transcatheter aortic valves will likely be implanted in lower-
risk patients. Recently presented results of the PARTNER
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Transcatheter Valve Technology July 5, 2011:123–4trial’s cohort A (patients with high surgical risk) suggest that
transcatheter aortic valve replacement is not inferior to
surgical valve replacement in preventing mortality at 1 year.
However, because the rates of neurological complications
favored surgical aortic valve replacement, the cohort A
results are not definitively in favor of the transcatheter valve
(4). Yet, this is not the final word on the subject. After all,
the CoreValve (Medtronic) has a completely different de-
sign, and Medtronic is just now embarking on a major
randomized clinical trial structured much like the PART-
NER trial. The Medtronic study will provide another
rigorous dataset comparing high-risk patients randomized
between surgery and percutaneous CoreValve implantation.
Furthermore, transcatheter valve technology will also be
applied to a wider spectrum of patient pathologies including
bicuspid aortic valves (5), failed stentless bioprostheses (6),
and possibly also to younger patients with aortic valve
disease.
Other steps are also being taken in completely different
arenas. For example, 3-dimensional models generated from
magnetic resonance images of dilated pulmonary trunks
found in patients with severe pulmonary insufficiency are
being used to design valved stent grafts suitable for percu-
taneous implantation (7,8). This work raises the possibility
that percutaneous valves may become available as the first
valve implant in patients with valve-less repair of tetralogy
of Fallot and other right heart maladies. Alternative ideas,
such as dual-valve implantation in the pulmonary artery
branches or surgical implant of a “valve landing zone”
consisting of an expandable ring during initial repair, may
have similar potential implications.
The mitral valve is also worthy of mention as it is a major
challenge for transcatheter valve technology. It should be
feasible to re-valve dysfunctional mitral tissue valves with
Sapien or Melody valves. Although individual cases may
have been attempted, none have been reported as of this
writing. On the other hand, it is noteworthy that an
unrelated technology, percutaneous mitral valve repair, is
showing considerable promise. The MitraClip System (Ab-
bott Laboratories, Abbott Park, Illinois), which employs
edge-to-edge technology, is the most developed. This tech-
nology is being compared with surgical valve repair in the
EVEREST II (Endovascular Valve Edge-to-Edge Repair
Study) trial (9). The results will undoubtedly be interesting.
Finally, valve and implant system designs are also evolv-
ing by numerous small steps. A variety of valves and valve
materials are being used, including intact bovine venous
valves, valves constructed from bovine or porcine pericar-
dium, and valves constructed of nitinol foil. A large number
of valve designs and technologies are being explored, in-cluding at least 17 different aortic valves. Improved valve
designs and technologies have facilitated reduction of per-
cutaneous implant systems to diameters as small as 16-F
(10). In addition, a variety of percutaneous and hybrid
techniques are being evaluated for valve implant. Taken all
together, these activities are facilitating development of
more functional and more durable valves, and permitting
valve implantation in smaller patients.
Today, the future role of transcatheter valve technology in
the “big picture” of valve repair and replacement therapies is
clear. It is fair to say that transcatheter valve technology will
continue to advance, and it will become a significant
alternative to traditional valve surgery. This technology is
challenging our assumptions and changing our practice. The
Roberts et al. (3) report is a harbinger of things to come.
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